ClinicalTrials.gg
RecruitingNCT06984484ARMORUpdated Aug 26, 2026

Performance and Safety of Afluxin® in Patients With Gastroesophageal Reflux Disease

An interventional study of Afluxin® and Placebo in Gastroesophageal Reflux Disease (GERD), sponsored by Devintec Sagl. Recruiting at 7 sites in Italy. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-26.

Sponsored by Devintec Sagl · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
208
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 78 studies in Gastroesophageal Reflux with a site in Italy — 12 open to participants now, 14 under way, none of them phase 3. Gastroesophageal Reflux · Italy.

Planned enrollment
14th of 48
208 · median 80
Started
2025
with 4 others
No phase
22 of 78
5 open now
Primary completion
2027-01
later than 7 of 13 live
Registered
69th of 78
by date

Among the 78 studies in Gastroesophageal Reflux with a site in Italy, this one is the 14th largest by planned enrollment of the 48 interventional ones that give a count, is one of 5 that started in 2025, is one of 22 with no phase, reaches primary completion later than 7 of the 13 other live ones, and was the 69th registered.

Gastroesophageal Reflux

1,216 studies on the registry are indexed under Gastroesophageal Reflux; 204 are open to participants now.

Browse Gastroesophageal Reflux studies →

Open to participants now

12 of the 78 studies in Gastroesophageal Reflux with a site in Italy are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 134 Gastroesophageal Reflux studies recruiting now, 58 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies in Gastroesophageal Reflux with a site in Italy, or all of them as a file.
02

Study summary

Gastroesophageal Reflux Disease (GERD) is a chronic condition in which stomach acid flows back into the esophagus, causing irritation and inflammation. GERD is categorized into Nonerosive Reflux Disease (NERD), Erosive Esophagitis (EE), and Barrett's esophagus (BE). Common symptoms include heartburn and acid regurgitation. Lifestyle factors such as smoking, obesity, and Helicobacter pylori infection can increase the risk of developing GERD. The clinical management of GERD typically involves Proton Pump Inhibitors (PPIs) therapy, which, although effective, may not benefit all patients and can be associated with long-term risks. The American College of Gastroenterology (ACG) suggests PPIs discontinuation or on-demand therapy for uncomplicated GERD after an 8-week trial. However, evidence indicates that PPIs are used more frequently, often long-term and in high doses, and not necessarily according to recommendations. Moreover, the availability of Over-The-Counter (OTC) PPIs has led to prolonged use by patients without medical guidance. Concerns have been raised due to potential side effects of long-term PPIs use, including enteric, respiratory, and urinary tract infections, as well as an increased risk of vitamin and mineral deficiencies and osteoporosis.

Alternatives to PPIs include Histamine-2 Receptor Antagonists (H2RAs), antacids and alginate-based formulations. Among OTC treatments, medical devices formulated with natural components are also gaining attention for their potential performance and tolerability in managing mild to moderate GERD symptoms. These alternatives could address the unmet needs of NERD patients, especially those with a low response to PPIs treatment and provide an option without the potential side effects of prolonged PPIs use. Afluxin® is a class III medical device, containing functional substances (tamarind seed polysaccharide, pea protein and polyacrylic acid), formulated for the treatment of mild to moderate GERD. Preclinical data have shown that Afluxin® is able to create a protective barrier over the gastroesophageal epithelium, preventing reflux damage. In vitro studies suggest that Afluxin® effectively binds to the esophageal and gastric mucosa, reducing abnormal permeability caused by acid reflux. Moreover, in vivo evidence shows that Afluxin® can increase gastric pH, reduce epigastric pain, esophageal damage, and inflammatory markers associated with GERD. Given the encouraging results obtained in preclinical investigations, this study is designed to provide clinical evidence to support the performance and safety of Afluxin® in reducing gastrointestinal symptoms of patients with mild to moderate GERD in a multicenter, randomized, double-blind, parallel-group, Afluxin® stick pack vs. inactive control clinical investigation.

03

Conditions studied

  • Gastroesophageal Reflux Disease (GERD)

Keywords

  • Gastroesophageal Reflux Disease
  • GERD
  • Afluxin
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female patients, aged ≥ 18 years and ≤ 75 years.
  2. Evidence of symptomatic GERD: patients with ongoing heartburn and/or regurgitation (with or without dyspepsia symptoms of epigastric pain and/or burning) of at least mild to moderate severity or experienced during the least 7 days before starting the treatment, as assessed on a clinical basis by the Investigator.
  3. Patients not pre-treated with PPIs, even for problems different from GERD (e.g., gastroprotection, PPI-based triple or quadruple therapy for eradication of H. pylori), H2RAs, and/or with antiacids, alginates or medical devices made of substances (i.e., substance-based medical devices to treat GERD, gastroesophageal reflux and similar conditions) in the last week prior to screening.
  4. Patient has provided written after being informed of the study procedures and risks prior to any study-related events.
  5. Patients are able to understand and adhere to the study procedures.
  6. Females of must have a negative urine pregnancy test (dipstick) at Visit 1 and currently use or agree to use consistently and correctly (i.e., perfect use) a highly effective or acceptable effective method for the individual subject and her partner(s) throughout the study treatment period.

Exclusion criteria

Exclusion Criteria:

  1. Patient with to any Afluxin® or inactive control components.
  2. Rhinosinusitis or bronchitis.
  3. Patients with a:

    1. history and/or
    2. symptom profile and/or
    3. discovered on endoscopy suggestive of the following: any other Gastrointestinal (GI) disease, erosive GERD, BE, acute peptic ulcer and/or ulcer complications, hiatus hernia with a diameter which exceeds 3 cm, Zollinger-Ellison syndrome, esophageal or gastric cancer, pyloric stenosis, esophageal or gastric surgery, intestinal obstruction, current pernicious anemia, indication for H. pylori eradication therapy, known gastro-intestinal bleeding (hematochezia or hematemesis) within the last 12 months.
  4. Patients diagnosed with functional dyspepsia characterized by postprandial distress syndrome (i.e., bothersome postprandial fullness and/or early satiation).
  5. Patients with a history of gastro-esophageal surgery, anti-reflux, or bariatric procedure.
  6. Presence of any active (except for non-invasive basal or squamous cell carcinoma of the skin).
  7. Patients using any drug that could affect symptoms or affecting the gastrointestinal tract during the last week prior to screening:

    1. prokinetics
    2. systemic glucocorticosteroids
    3. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
  8. Patients who are pregnant or lactating.
  9. Patients who are enrolled in or have participated in other clinical trials or investigations within 30 days prior to screening.
  10. or unstable concurrent diseases whose sequelae or treatment might contraindicate study participation or interfere with the study evaluation parameters, as judged by the Investigator.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
208 participants (estimated)

Study arms

  • Experimental
    Afluxin®

    Afluxin® is a medical device not CE marked yet. According to the Annex VIII of MDR 2017/745 it belongs to class III (Rule 21). Afluxin® stick pack is an oral suspension to be taken without any liquid 3 times a day after breakfast, lunch and before going to bed. Afluxin® does not contain any medicinal substances, human or animal tissues or their derivatives, or other biologically active substances coming in contact with the patient. The composition of one stick pack of Afluxin® is the following: purified water, isolated pea proteins, tamarind seed polysaccharide (Tamarindus indica L.), polyacrylic acid, propyl 4-hydroxybenzoate sodium salt, sodium methylparaben, strawberry aroma, mint aroma, sodium hydroxide, sucralose.

    Device: Afluxin®

  • Placebo comparator
    Placebo

    Placebo is an inactive preparation designed to match the active treatment in taste and have a similar color (white-transparent) to Afluxin®.

    Drug: Placebo

Interventions

  • DeviceAfluxin®

    Afluxin® stick pack is an oral suspension to be taken without any liquid 3 times a day after breakfast, lunch and before going to bed, for 7 days.

  • DrugPlacebo

    Inactive control stick pack is an oral suspension to be taken without any liquid 3 times a day after breakfast, lunch and before going to bed, for 7 days.

06

What researchers measure

Primary outcomes

  1. Assess the superiority of a 7-day treatment course with Afluxin® over inactive control in terms of difference between treatment groups in terms of proportion of responders

    The primary endpoint is the difference between treatment groups (Afluxin® and placebo) in terms of proportion of responders, defined as patients who report a reduction in the GERD dimension of the RDQ (Reflux Disease Questionnaire) equal to 1.5 points (clinically significant difference, according to Wilkinson et al., 2019), between baseline and the end of the 7-day treatment. In the RDQ questionnaire validated in Italian language, patients are asked to rate GERD-related symptoms they have been experiencing over the past 7 days. The questionnaire consists of 12 items to report the frequency and severity of heartburn, regurgitation and dyspepsia. In this study the two subscales for heartburn and regurgitation will be combined into the GERD dimension. Symptom frequency and severity will be measured on 6-point scales (ranging from 0=none to 5 =daily/severe).

    Time frame: From enrollment to the end of the 7-day treatment

Secondary outcomes

  1. RDQ GERD dimension, including single item scores

    GERD dimension evaluated through the RDQ (Reflux Disease Questionnaire) and evaluation of the single item scores, at the baseline and at the end of the 7-day treatment. In the RDQ questionnaire validated in Italian language, patients are asked to rate GERD-related symptoms they have been experiencing over the past 7 days. The self-assessed questionnaire will consist of 12 items to report the frequency and severity of heartburn, regurgitation and dyspepsia. The two subscales for heartburn and regurgitation will be combined into the GERD dimension. Symptom frequency and severity will be measured on 6-point scales (ranging from 0=none to 5 =daily/severe).

    Time frame: Baseline and at the end of the 7-day treatment

  2. RDQ dyspepsia dimension total and single item scores

    Dyspepsia dimension evaluated through the RDQ (Reflux Disease Questionnaire) total and single item scores, at the baseline and at the end of the 7-day treatment. In the RDQ questionnaire validated in Italian language, patients are asked to rate GERD-related symptoms they have been experiencing over the past 7 days. The self-assessed questionnaire will consist of 12 items to report the frequency and severity of heartburn, regurgitation and dyspepsia (burning/pain in the upper stomach). Symptom frequency and severity will be measured on 6-point scales (ranging from 0=none to 5 =daily/severe).

    Time frame: Baseline and at the end of the 7-day treatment

  3. Total and single item scores of the Reflux Symptom Index (RSI)

    Total and single item scores of the Reflux Symptom Index (RSI) at baseline and at the end of the 7-day treatment, assessing the severity of Laryngopharyngeal Reflux (LPR) symptoms. The RSI validated in Italian language, will be used for the evaluation of LPR symptoms that patients have been experiencing within the last month. The RSI examines 9 items, to be scored from 0 (no problem) to 5 (severe problem), with a higher score indicating a higher severity of the symptom (range of total score: 0-45) .

    Time frame: Baseline and at the end of the 7-day treatment

  4. Severity of GERD cardinal symptoms (i.e., heartburn and regurgitation)

    Severity of GERD cardinal symptoms (i.e., heartburn and regurgitation) throughout the 7-day treatment, as self-assessed daily by patients using a 7-point Likert scale ranging from 1 = no discomfort to 7 = very severe discomfort.

    Time frame: Throughout the 7-day treatment

  5. Severity of LPR symptoms (i.e., hoarseness/clearing the throat and troublesome cough)

    Severity of (Laryngopharyngeal Reflux) LPR symptoms (i.e., hoarseness/clearing the throat and troublesome cough) throughout the 7-day treatment, as self-assessed daily by patients using a 7-point Likert scale ranging from 1 = no discomfort to 7 = very severe discomfort.

    Time frame: Throughout the 7-day treatment

  6. Number and percentage of patients with occurrence of symptoms during the night

    Number and percentage of patients with occurrence of symptoms during the night throughout the 7-day treatment

    Time frame: Throughout the 7-day treatment

  7. Mean time to alleviation of symptoms following treatment administration

    Mean time to alleviation of symptoms following treatment administration throughout the 7-day treatment, as self-assessed daily by patients

    Time frame: Throughout the 7-day treatment

  8. Number and percentage of patients with complete remission of symptoms

    Number and percentage of patients with complete remission of symptoms at the end of the 7-day treatment, defined as an RDQ (Reflux Disease Questionnaire) GERD dimension total score = 0 points. In the RDQ questionnaire validated in Italian language, patients are asked to rate GERD-related symptoms they have been experiencing over the past 7 days. The self-assessed questionnaire will consist of 12 items to report the frequency and severity of heartburn, regurgitation and dyspepsia. Symptom frequency and severity will be measured on 6-point scales (ranging from 0=none to 5 =daily/severe).

    Time frame: At the end of the 7-day treatment

  9. Mean score on the self-report measure Patient's Global Impression of Change (PGI-C)

    Mean score on the self-report measure Patient's Global Impression of Change (PGI-C) at the end of the 7-day treatment, assessing the patient's overall perceived change in their condition. The self-report measure PGI-C will be used to assess the overall perceived improvement at the end of the 7-day treatment. Patients will reply to the general statement "Since the start of the study, my overall status is'", using the following 7-point scale: 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, and 7=very much worse.

    Time frame: At the end of the 7-day treatment

  10. Number and percentage of patients who take prohibited medications

    Number and percentage of patients who take prohibited medications (Proton Pump Inhibitors, Histamine-2 Receptor Antagonists, antiacid, alginates or medical devices made of substances).

    Time frame: Throughout the 7-day treatment

  11. Patient's compliance with treatment

    Patient's compliance with treatment protocol, in terms of adherence to the instructions and recommendations of the study treatment protocol. The information are recorded on the patient's diary and reviewed by the investigators. Patient differences in % compliance between the two treatments will be calculated.

    Time frame: Throughout the 7-day treatment

  12. Patient's satisfaction with treatment

    Patient's satisfaction with treatment, as self-assessed by the patient using a 5-point response scale, at the end of the 7-day treatment. At the end of the 7-day treatment the patient will record his/her opinion of satisfaction with treatment in the e-diary, answering the question: "How satisfied are you with the study treatment you received?" with a 5-point response scale (1=unsatisfied, 2=somewhat unsatisfied, 3=neutral, 4=somewhat satisfied, 5=satisfied).

    Time frame: At the end of the 7-day treatment

  13. Safety: adverse events and device deficiencies

    Incidence and type of AEs and DDs continuously monitored during the study

    Time frame: Throughout the 7-day treatment

07

Study locations

7 of 7 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Jan 2027, 18 months after the start.

Of 34 industry-sponsored interventional studies with no phase under Gastroesophageal Reflux, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 18 months is below that.

Counting every sponsor, half of 228 studies reached it within 32 months; a quarter within 12 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2025
First posted
May 22, 2025
StartActual
Jul 2, 2025
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2027
Last update
Aug 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06984484
Lead sponsor
Devintec Sagl
Responsible party
Sponsor
First posted
May 22, 2025
Start date
Jul 2, 2025
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
Aug 26, 2026

Study contacts

Daniela Salvati
Contact
daniela.salvati@prineos.com
+39 3334828012
Maria Dini
Contact
maria.dini@prineos.com
+39 3383236335

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion